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ABSTRACT
Staphylococcus aureus is a very versatile and adaptable microorganism. It can potentially 
infect virtually any host tissue. Given the appropriate conditions it can become a life-
threatening pathogen, or a commensal colonizer of the nose. Extensive antibiotic use for 
infection control facilitated the rise of antibiotic resistance, stressing the need for alternate 
forms of control. Vaccine efforts in other pathogens have proved successful, but so far S.  
aureus candidate vaccines have not been as effective. Here we review S. aureus factors 
involved in pathogenesis that could help develop a successful vaccine, like host nasal 
colonization and immune evasion factors. An effective multicomponent vaccine could 
incorporate antigenic fragments from several S. aureus proteins, preferably involved in 
colonization, immune evasion and/or toxicity.
KEYWORDS: S. aureus, Vaccine, Nasal colonization, Immune evasion.
INTRODUCTION
Staphylococcus aureus is a natural inhabitant of mammalian skin and certain mucous 
epithelia. It is an opportunistic pathogen and has the ability to infect virtually every tissue 
in the body of animals and humans, especially those at risk of infection like wounds, or 
with diminished immunological protection like secretory glandular tissue (28).  It is a very 
versatile and adaptable organism; it can become pathogenic causing bacteremia or establish 
a commensal relationship in humans without causing overt disease, as is the case in nasal 
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colonization. However, given the appropriate conditions each and every strain of S. aureus 
can become a life-threatening pathogen (29).
Infection control usually requires antibiotics; however, their extensive use has facilitated 
the emergence of strains with antibiotic resistance (21). Resistance to methicillin and 
vancomycin has been observed in recent years in hospital and community acquired S. 
aureus infections (5, 44). Methicillin resistance in S. aureus is mediated by the acquisition 
of an exogenous gene, mecA, that encodes a ß-lactam-resistant penicillin-binding protein 
(PBP), termed PBP 2a (or PBP2') (22). There are two known types of vancomycin 
resistance, complete (vancomycin-resistant S. aureus, VRSA) and intermediate resistance 
(vancomycin intermediate resistant S. aureus, VISA). The VRSA resistance is mediated via 
the apparent acquisition of the vanA gene that allows synthesis of modified peptidoglycan 
precursors with decreased affinity for vancomycin. In VISA, genetic mutations that result 
in production of a much thicker cell wall makes it very difficult for vancomycin to enter the 
cell (10).
In this review we will present a summary of S. aureus nasal colonization and immune 
evasion mechanisms used to overcome host responses, as well as strategies used in vaccine 
design. Based in this information, we then suggest desirable characteristics that future 
vaccine candidates may incorporate in their design. 
Nasal colonization
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The association between S. aureus nasal carriage and staphylococcal disease was first 
reported by Danbolt in 1931 (45), which numerous studies confirmed afterwards (48, 53, 
54). Several studies including historical medical controls have reported great reductions of 
surgical site infections in patients pre-treated to remove S. aureus from their noses -nasal 
decolonization- (7, 25). Although nasal carriage is one of the most important risk factors for 
nosocomial and surgical site infections, randomized controlled trials have failed to confirm 
a significant reduction in infection rates after nasal decolonization (24). Therefore, 
clearance of nasal S. aureus is not a completely effective method for infection control. It is 
possible that after nasal clearance, S. aureus that reside in other parts of the body are the 
source of infection. S. aureus cells can survive for months on many types of surface (26), 
and propagate from there through the hands of the patient (or relatives or caregivers) to the 
site of infection, or even back to the nasal niche by nose picking (52).
Longitudinal studies distinguish at least three nasal carriage patterns in healthy individuals: 
persistent carriage (about 20%), intermittent carriage (30%), and non-carriage (50%) (14, 
47, 54). Persistent carriers have higher single-strain S. aureus loads (their "persistent 
strain") and higher risk of developing staphylococcal infections (34), while intermittent 
carriers may carry different strains over time (14, 47). Furthermore, after inoculation with a 
mix of S. aureus strains, non-carriers quickly eliminate all strains, whereas persistent 
carriers eliminate all strains except for their "persistent strain" when it was present in the 
inoculation mix (33). It is important to notice that non-carriers who become infected from 
exogenous S. aureus strains have a four-fold increased mortality rate compared with S. 
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aureus nasal carriers (53). The host immune response that kept non-carriers noses free from 
S. aureus is not effective enough to prevent other S. aureus infections.
Recently, a study of anti-staphylococcal antibodies profile showed that levels of IgG and 
IgA against 17 different S. aureus antigens were equal in intermittent carriers and non-
carriers but not in persistent carriers. This suggests there are only 2 types of nasal carriers: 
persistent and non-persistent carriers (46). 
Nasal carriage patterns are most likely determined by host and bacterial factors. No relation 
has been observed between carriage rate and seasonality, temperature, or relative humidity 
(30, 31, 54). Genetic studies have shown that a simple Mendelian trait probably does not 
explain host carrier states (1, 3, 36). However, there are observed differences in bacterial 
attachment to the nasal epithelia of carriers and non-carriers that suggest host factors 
(genetic and/or environmental) can determine carrier state (2). Personal environmental 
factors probably have a larger influence: carrier states are usually shared among household 
members and most mothers carry the same strain as their children (36), suggesting that 
close contact helps adaptation of the pathogen to its host. Even the anatomy of the nose 
may influence carrier state (9, 38).
In summary, the existence of non-carriers suggest that there is an immune host response, 
and probably some genetic host factors as well, that is effective in preventing S. aureus 
colonization. Even in carriers, there is a balance between host and pathogen that allows 
only a specific strain to colonize and prevents colonization from other strains. However, 
this balance is lost when S. aureus manages to thwart host defenses and invades the host. It 
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is likely that genetic changes in the strain are partly responsible for the newly developed 
abilities of the strain to overcome the host immune response (20), probably aided by host 
changes, like wounds or diminished immune defenses, that facilitate infective processes. 
It may be possible to elicit an immune response through vaccination that allows the host to 
defend against invading bacteria, one that mimics the immune response of non-carriers. 
Studies in host immune responses have identified S. aureus molecules that react strongly to 
sera of non-carriers. Identified molecules are usually involved in immune evasion and 
colonization mechanisms by S. aureus (13, 49).
Immune evasion
Usually after host internalization, a microorganism and its products are taken up by 
macrophages and other antigen-presenting cells and transported to lymph nodes, where B 
cells are stimulated to differentiate and secrete antibodies that neutralize toxins and 
promote more efficient phagocytosis of bacterial cells. Antibodies to S. aureus antigens can 
be detected in all humans, and titers usually rise after infection (13, 16, 40). However, these 
antibodies and immunological memory seem to be inadequate to prevent subsequent 
infections, which reflect the great capacity of S. aureus to compromise immune responses.
S. aureus has an impressive number of immune evasion factors to overcome host defense 
mechanisms (11, 17). It is important to notice that many of these factors have multiple, 
often redundant roles: if one of them is rendered inactive through mutation or antibody 
targeting, its function can still be carried away by another redundant factor (Figure 1). 
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After the physical barrier of the skin is breached and the bacterium starts to grow inside the 
host, the innate immune response is activated (50). S. aureus is particularly adept in 
evading innate host defense, as evidenced by the abundance of mechanisms that the 
bacterium uses to evade killing by phagocytes (17). 
Complement activation is part of the innate immune response, and S. aureus has several 
bacterial products that interfere with its function by (i) the recruitment or mimicking of 
complement regulators, (ii) the modulation or inhibition of complement proteins by direct 
interactions, and (iii) the inactivation by enzymatic degradation (27). Phagocyte function is 
also altered by S. aureus, expressed S. aureus molecules can block phagocyte receptor 
function. Bacteria may hide from recognition by producing protective coats, such as 
capsular polysaccharide or biofilm. After ingestion by professional or non-professional 
phagocytic cells, the bacteria use mechanisms to decrease the efficiency of antimicrobial 
mechanisms and to survive killing mechanisms. Intracellular persistence provides a 
protective niche from professional phagocytes and extracellular antibiotics, and can 
promote recrudescent infection (19). S. aureus often produce toxins that lyse phagocytes 
and superantigen toxins that overstimulate the immune system (11, 17). The tight control of 
expression is also essential for pathogenesis. The expression of toxins, colonization and 
immune evasion factors is controlled by complex regulatory networks that include the 
quorum-sensing agr system, transcriptional regulators of the sar family, the two-
component regulatory systems ArlRS and SaeRS, and the alternative sigma factor SigB 
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(35). A more detailed review of S. aureus molecules that contribute to immune evasion or 
alter host immune function is presented elsewhere (11, 17).
Vaccine designs.
Is a S. aureus vaccine feasible? This is not a question with an easy answer. Recovery from 
a S. aureus infection does not appear to confer immunity against subsequent infections, 
which cast doubts in the feasibility of generating a better protective immune response than 
the one induced after natural infection. However, work in the prevention of bovine mastitis 
(32) showed a 50-70% protection level when using killed bacteria combined with α- and β-
toxin toxoids, indicating that it may be possible to generate an immune response with an 
improved level of protection. Since it is not appropriate to use whole killed S. aureus 
vaccine preparations in humans, alternatives have to be found. 
Several reviews covering vaccine development have been published (12, 39, 42). 
Concisely, the few vaccine candidates that have advanced to clinical trials have failed to 
show positive results, even after having shown excellent results in animal models of 
infection. Lessons learned in other pathogens might not be transferable to S. aureus. For 
example, vaccines based in capsular polysaccharides of other bacterial pathogens have 
proven successful (15, 18), whereas in S. aureus failed to show protection (43). Important 
efforts are directed towards creating staphylococcal subunit vaccines (39), although one 
could argue that a vaccine carrying only one bacterial factor as immunogen might not work 
due to the ample role redundancy of S. aureus molecules (Figure 1). 
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Another approach consists of letting the human immune response choose the best target for 
vaccination (8, 13, 49, 51). Sera of carriers vs. non-carriers, or healthy vs. infected human 
subjects is probed against a library of expressed S. aureus proteins, with the idea of identify 
potential targets already recognized by a "good" human immune response to be used as 
candidate vaccines. This approach has its strength in that bacterial proteins recognized by 
human sera with a high antibody titer and opsonic activity against S. aureus in vitro, are 
more likely to perform better as vaccine components than bacterial proteins not recognized. 
Its weakness resides in that selected targets are only as effective as the antibodies used to 
select them. The fact that non-carriers that successfully fend off S. aureus from colonizing 
their noses can still become severely ill from a S. aureus infection means their antibodies 
are not completely capable of excluding S. aureus under all conditions.
There is also the possibility that an identified S. aureus candidate antigen in its fully 
functional state is poorly antigenic, resulting in few or no induced antibodies in the host. 
Mice immunized with fibronectin-binding protein (FnBP) were able to resist an S. aureus 
infection challenge (6, 41), but were unable to block binding of FnBP to host fibronectin. It 
was found that native FnBP is poorly immunogenic, but after binding to fibronectin, the 
FnBP-fibronectin complex is actually immunogenic (37). Therefore, induced antibodies 
were actually recognizing the FnBP-fibronectin complex instead of preventing its binding. 
It was later found that biologically inactive FnBP fragments were actually capable of 
inducing antibodies that could recognize native FnBP and prevent its binding to fibronectin, 
therefore being better immunogens than native FnBP (4, 23) (Figure 2).
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Therefore, it is possible that an effective vaccine could incorporate antigenic fragments 
from several S. aureus proteins, a multicomponent vaccine, preferably involved in 
colonization, immune evasion and/or toxicity (Table 1). These antigenic fragments would 
be biologically inactive proteins that could still induce protective antibodies. The absence 
of biologically active antigens can increase safety and the targeting of multiple S. aureus 
proteins at once decreases the chances of S. aureus immune evasion.
CONCLUSSION
A successful vaccination protocol could greatly contribute to S. aureus infection control, 
providing a much needed relief in reliance of antibiotic therapy alone. Also, advances in the 
field will help develop effective passive immunization protocols, which are useful in cases 
were prophylactic vaccination is not possible. Much work is still needed, but the field has 
greatly progressed lately, with a growing number of research groups working in S. aureus 
vaccine development, as observed after a Pubmed search in S. aureus vaccines 
(http://www.ncbi.nlm.nih.gov/sites/entrez/ access date: July 2009). It is likely that S.  
aureus infection control can be achieved soon.
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Table 1. Possible targets for vaccine development
aaa Autolysin / adhesin from S. aureus
atl S. aureus autolysin
aur Zinc metalloproteinase aureolysin, Aur
bbp Bone sialo-protein binding protein
cap5 / cap8  Capsular polysaccharide 
chp Chemotaxis inhibitory protein of S. aureus
clfA, ClfB Clumping factor A and B
can Collagen binding protein
coa Staphyloccocal coagulase
crtM, crtN Carotenoid pigment, staphyloxanthin
dltc DltC, from Dlt operon, DltABCD 
eap Extracellular adherence protein
ebh extracellular matrix (ECM) binding protein homologue
ebps Elastin binding protein
ecb Extracellular complementbinding protein
efb Extracellular fibrinogenbinding protein
emp Extracellular matrix protein-binding protein
fbpa Fibrinogen binding protein 
fnbA, fnbB Fibronectin-binding proteins A and B
hla, hly Alpha-hemolysin (α-hemolysin)
hld Delta-hemolysin
hlgA, hlgB, hlgC Gamma-hemolysin subunits A, B, and C 
icaD, icaB, icaC Polysaccharide intercellular adhesin, PIA
isdA, isdB Iron-regulated surface determinants of S aureus,
lukS-PV, lukF-PV Leukocidin S-PV and F-PV, Panton Valentine leukocidin
lukD, lukE Leukocidin D and E 
mprF Multiple peptide resistance factor
pls plasmin sensitive protein PLS
psm Phenol-soluble modulinlike peptides
rap RANIII activating protein
sak Staphylokinase 
sasg S. aureus surface protein G
sbi IgG-binding protein
scn Staphylococcal inhibitor of complement
sea, seb, secn, sed, see, seg, Staphylococcal enterotoxins
    seh, sei, sej, sek, sel, sep
spa Protein A 
ssl5 Staphylococcal superantigen-like 5, SSL5
ssl7 Staphylococcal superantigen-like 7, SSL7
tst Toxic shock syndrome toxin-1, TSST1
vnbp Vibronectin binding protein
vwbp Von Willebrand factor binding protein
eno α-enolase, Laminin binding protein 
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ecb
chp
spa
sak
eap
fnbpA,B
emp
clfA,B
C3 Complement
C5 Complement
Immunoglobulins
Lymphocyte activation
cationic defensins
plasminogen
Prothrombin 
Fibronectin 
Fibrinogen
Elastin
Vitronectin
Keratin 
Fibrin 
Figures:
Figure 1. Redundancy in S. aureus. Expressed products of S. aureus genes involved in 
pathogenicity, colonization and/or immune evasion usually interact with several targets. 
Additionally, host factors are usually targeted by different bacterial factors. Redundancy 
assures infection processes can continue even when some bacterial factors are neutralized 
by host responses or vaccination
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native FnBP 
immunization
antibodies bind 
FnBP-Fn complex
X
FnBP fragment 
immunization
antibodies prevent 
FnBP-Fn complex
Y
Y
Y
Fn
BP
Fn
Y
Y
Y
YY
Fn
BP
Y
Y Y Y
Fn
BP Fn Y Y
Y
XFnB
P
FnX
Figure 2. Immunization with FnBP. Immunization with native FnBP induces antibodies 
that fail to prevent binding of FnBP to Fn, by failing to recognize native FnBP; but 
recognizes the FnBP-Fn complex. Immunization with biologically inactive FnBP fragments 
induces antibodies effective in preventing binding of FnBP to Fn, by recognizing native 
FnBP and failing to bind the FnBP-Fn complex.
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